결합조직질환 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the connective tissue disease market size is expected to increase from USD 16.53 billion in 2025 to USD 17.46 billion in 2026 and reach USD 23.54 billion by 2031, growing at a CAGR of 6.16% over 2026-2031.

This report is Segmented by Disease (RA, SLE, Scleroderma, Polymyositis, Dermatomyositis, Sjogren's Syndrome, MCTD, UCTD), Drug Class (Biopharmaceuticals, Pharmaceuticals), Route of Administration (Oral, Injectable, Topical), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Connective Tissue Disease Market Trends and Insights

New Options for Lupus Nephritis and SSc-ILD

Within the connective tissue disease treatment market, lupus nephritis is moving into a more competitive phase because obinutuzumab added a new anti-CD20 option in late 2025. FDA approval in October 2025 and European Commission approval in December 2025 gave clinicians a new option with phase 3 backing in active Class III and IV disease. In REGENCY, 46.4% of patients achieved complete renal response versus 33.1% on standard therapy, which gave prescribers and payers a clearer basis for wider uptake. In SSc-ILD, 3-year SENSCIS-ON data supported continued nintedanib use, and a 2025 network meta-analysis ranked tocilizumab highest for slowing FVC decline across evaluated options. As these data accumulate, the connective tissue disease treatment market is moving away from narrow rescue options and toward more defined treatment pathways in lupus nephritis and fibrosing lung involvement.

ACR/CHEST ILD Screening Expansion

The connective tissue disease treatment market is also benefiting from a more structured ILD care pathway after the ACR and CHEST jointly set screening and monitoring recommendations for RA, SSc, IIM, MCTD, and Sjogren disease. The guideline recommends HRCT chest and pulmonary function testing at presentation for high-risk patients, which increases the chance that lung involvement is identified before advanced progression. It also supports close monitoring in the first year for IIM-ILD and SSc-ILD, which reduces the time between rheumatology follow-up and pulmonary referral. The companion treatment guideline names nintedanib and tocilizumab among conditional first-line options, so diagnosis is translating more directly into therapy selection. In Europe, the 2025 ERS and EULAR guidance widened this framework by including SLE and adding 25 PICO-based recommendations, which support reimbursement and practice alignment across the region.

High Biologic and Specialty-Drug Costs

Even with broader treatment choice, the connective tissue disease treatment market still faces an access ceiling because biologics remain expensive for many patients. A 2025 systematic review in The American Journal of Managed Care found that more than 70% of U.S. dermatology patients cited high out-of-pocket costs as a main barrier to biologics for immune-mediated disease. The same cost pressure matters in CTD care because lupus, rheumatoid arthritis, and related disorders often require long treatment duration and repeated monitoring. Price negotiation and biosimilar entry can reduce acquisition cost, but they do not fully remove affordability gaps once co-pays, deductibles, and site-of-care charges are included. This means the connective tissue disease treatment market can expand clinically faster than it expands in real-world treated volume, especially in systems with tighter reimbursement controls.

Other drivers and restraints analyzed in the detailed report include:

1. CAR-T Pipeline in Refractory Lupus
2. Home-Administration Expansion in Lupus Biologics
3. Safety Monitoring Burden for JAKs and Immunosuppressants

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Rheumatoid arthritis held 41.23% of the connective tissue disease treatment market share in 2025, which gave the connective tissue disease treatment market its largest disease revenue base. That position reflects higher diagnosed volume, a mature biologic treatment pathway, and long-standing physician familiarity with DMARD and biologic sequencing. Systemic lupus erythematosus is projected to expand at 8.23% CAGR through 2031, making it the fastest-growing disease segment in the connective tissue disease treatment market. Late 2025 and 2026 approvals of obinutuzumab, subcutaneous anifrolumab, and the pediatric belimumab autoinjector widened options across lupus nephritis and broader SLE care. A phase 3 telitacicept study in China also reported 67.1% SRI-4 response versus 32.7% on placebo at 52 weeks, which shows that the SLE pipeline is deepening beyond current marketed agents.

In the connective tissue disease treatment market, scleroderma or systemic sclerosis is gaining support from a two-drug ILD treatment pattern built around nintedanib and tocilizumab. Sjogren's syndrome remains a clear white space because no biologic has global approval, which keeps interest high in BAFF-pathway and adjacent autoimmune programs. Polymyositis and dermatomyositis remain smaller segments, but the unmet need is acute because dermatomyositis patients waited a mean 24.3 weeks to diagnosis and were initially misdiagnosed in 34% of cases in a 2025 survey. Mixed connective tissue disease and undifferentiated CTD still rely heavily on therapies borrowed from adjacent indications, while new ILD screening protocols are improving the odds that these patients reach specialist care sooner.

Biopharmaceuticals accounted for 63.12% share of the connective tissue disease treatment market size in 2025, and biologics remained the main value driver in the connective tissue disease treatment market. TNF-alpha inhibitors, IL-6 receptor antagonists, and BLyS inhibitors anchor this category because they are used across larger disease pools and established treatment pathways. The class also benefits from repeated label expansion and more defined use in lupus nephritis and CTD-ILD. Japan's 2025 to 2026 PMDA cycle approved subcutaneous anifrolumab for SLE and new tocilizumab biosimilars, which support both innovation and lower-cost biologic access. This keeps biopharmaceuticals central even when price competition increases in mature markets.

Pharmaceuticals are projected to grow at 7.93% CAGR through 2031, which makes them the fastest-growing drug class in the connective tissue disease treatment market. JAK inhibitors and other immunosuppressants still have room to expand in settings where biologic penetration remains uneven, while NSAIDs, corticosteroids, and conventional DMARDs continue to support large prescription volumes. The PMDA also approved upadacitinib for giant cell arteritis in the 2025 to 2026 cycle, showing continued regulatory support for targeted oral immunology agents. At the same time, the April 2025 RINVOQ label and the October 2025 XELJANZ label keep monitoring obligations visible, which shapes how fast this part of the connective tissue disease treatment market can scale.

Geography Analysis

North America held 43.62% of the connective tissue disease treatment market share in 2025, which kept the region at the center of global revenue. The United States accounts for most of that base because specialist access, biologic availability, and reimbursement depth remain stronger than in many other regions. In 2026, FDA-backed product expansion is still widening the treatable pool, especially after approvals for subcutaneous anifrolumab and the pediatric belimumab autoinjector. The connective tissue disease treatment market in North America also benefits from clear guideline support for CTD-ILD screening and treatment, which helps move high-risk patients toward earlier intervention. This keeps the region strong in both established rheumatoid arthritis care and higher-growth lupus and ILD use cases.

Europe remains the second-largest regional block in the connective tissue disease treatment market, supported by broad specialist networks and a well-established biologic treatment base. The December 2025 European Commission approvals for Gazyvaro in lupus nephritis and subcutaneous Saphnelo in SLE added fresh momentum in severe lupus care. The 2025 ERS and EULAR CTD-ILD guideline also extended the policy framework to SLE, which supports more standardized lung screening and treatment decisions across the region. Western Europe is likely to remain the main demand center, while Southern and Eastern markets add incremental volume as biosimilar and monitoring pathways mature.

Asia-Pacific is projected to grow at 9.18% CAGR through 2031, making it the fastest-growing region in the connective tissue disease treatment market size. Japan is helping drive that pace because the PMDA approved subcutaneous anifrolumab for SLE, upadacitinib for giant cell arteritis, and new tocilizumab biosimilars in the 2025 to 2026 cycle. Regional disease detection is also improving, and a 2025 meta-analysis reported pooled systemic sclerosis incidence in Asia-Pacific at 3.20 per 100,000 person-years, with post-2013 criteria identifying far more cases than older definitions. China, South Korea, India, and Australia remain important volume opportunities for the connective tissue disease treatment market as biologic access and specialist diagnosis continue to widen. The Middle East, Africa, and South America still hold smaller shares, but they add gradual demand where public reimbursement and urban specialist capacity can support higher-cost autoimmune care.

1. Abbvie
2. Amgen
3. AstraZeneca
4. Aurinia Pharmaceuticals Inc.
5. Bayer
6. Biogen
7. Boehringer Ingelheim
8. Bristol-Myers Squibb
9. Calliditas Therapeutics AB
10. Eli Lilly and Company
11. F. Hoffmann-La Roche Ltd. / Genentech, Inc.
12. GlaxoSmithKline
13. Johnson & Johnson Innovative Medicine
14. Merck
15. Novartis
16. Pfizer
17. Regeneron Pharmaceuticals
18. Sanofi
19. Teva Pharmaceutical Industries
20. UCB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diagnosed Autoimmune CTD Burden
  • 4.2.2 Biologics and Targeted Therapy Penetration
  • 4.2.3 New Options for Lupus Nephritis and SSC-ILD
  • 4.2.4 ACR/CHEST ILD Screening Expansion
  • 4.2.5 CAR-T Pipeline in Refractory Lupus
  • 4.2.6 Home-Administration Expansion in Lupus Biologics
• 4.3 Market Restraints
  • 4.3.1 High Biologic and Specialty-Drug Costs
  • 4.3.2 Safety Monitoring Burden for JAKs and Immunosuppressants
  • 4.3.3 Cell-Therapy Delivery and Long Follow-Up Constraints
  • 4.3.4 Delayed Diagnosis in Overlap and Seronegative CTD Cases
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Disease
  • 5.1.1 Rheumatoid Arthritis
  • 5.1.2 Systemic Lupus Erythematosus
  • 5.1.3 Scleroderma / Systemic Sclerosis
  • 5.1.4 Polymyositis
  • 5.1.5 Dermatomyositis
  • 5.1.6 Sjogren's Syndrome
  • 5.1.7 Mixed Connective Tissue Disease
  • 5.1.8 Undifferentiated Connective Tissue Disease
• 5.2 By Drug Class
  • 5.2.1 Biopharmaceuticals
    • 5.2.1.1 Biologics
    • 5.2.1.2 Biosimilars
  • 5.2.2 Pharmaceuticals
    • 5.2.2.1 NSAIDs
    • 5.2.2.2 DMARDs
    • 5.2.2.3 Corticosteroids
    • 5.2.2.4 Immunosuppressants
    • 5.2.2.5 Antimalarial Drugs
    • 5.2.2.6 Other Pharmaceuticals
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Injectable
    • 5.3.2.1 Intravenous
    • 5.3.2.2 Subcutaneous
  • 5.3.3 Topical
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 AbbVie Inc.
  • 6.3.2 Amgen Inc.
  • 6.3.3 AstraZeneca plc
  • 6.3.4 Aurinia Pharmaceuticals Inc.
  • 6.3.5 Bayer AG
  • 6.3.6 Biogen Inc.
  • 6.3.7 Boehringer Ingelheim International GmbH
  • 6.3.8 Bristol Myers Squibb Company
  • 6.3.9 Calliditas Therapeutics AB
  • 6.3.10 Eli Lilly and Company
  • 6.3.11 F. Hoffmann-La Roche Ltd. / Genentech, Inc.
  • 6.3.12 GSK plc
  • 6.3.13 Johnson & Johnson Innovative Medicine
  • 6.3.14 Merck & Co., Inc.
  • 6.3.15 Novartis AG
  • 6.3.16 Pfizer Inc.
  • 6.3.17 Regeneron Pharmaceuticals, Inc.
  • 6.3.18 Sanofi
  • 6.3.19 Teva Pharmaceutical Industries Ltd.
  • 6.3.20 UCB S.A.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment